- Cambridge, MA-based Magenta Therapeutics (NASDAQ:MGTA) has filed a preliminary prospectus for a $100M IPO.
- The clinical-stage biotech develops treatments that extend the curative power of bone marrow transplantation, specifically a stem cell biology discovery platform and portfolio of novel therapeutics that the company says enables much safer patient preparation and improved prospects for success. Lead candidate is Phase 2-stage MGTA-456, a cell therapy derived from cord blood for the potential treatment of blood cancers and inherited metabolic diseases.
- 2018 Financials (Q1)($M): Operating Expenses: 11.3 (+135.4%); Net Loss: (11.2) (-116.1%); Cash Burn: (9.6) (-138.3%).
- HSCT-related tickers: BLCM, OMER, NVS, APOP
Magenta Therapeutics on deck for IPO
Recommended For You
About DNTH Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
DNTH | - | - |
Dianthus Therapeutics, Inc. |